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Abstract The COX-2 protein is frequently overexpressed
in human malignant gliomas. This expression has been
associated with their aggressive growth characteristics and
poor prognosis for patients. Targeting the COX-2 pathway
might improve glioma therapy. In this study, the effects of
the selective COX-2 inhibitor meloxicam alone and in
combination with irradiation were investigated on human
glioma cells in vitro. A panel of three glioma cell lines
(D384, U87 and U251) was used in the experiments from
which U87 cells expressed constitutive COX-2. The re-
sponse to meloxicam and irradiation (dose-range of 0–
6 Gy) was determined by the clonogenic assay, cell pro-
liferation was evaluated by growth analysis and cell cycle
distribution by FACS. 24–72 h exposure to 250–750 lM
meloxicam resulted in a time and dose dependent growth
inhibition with an almost complete inhibition after 24 h for
all cell lines. Exposure to 750 lM meloxicam for 24 h
increased the fraction of cells in the radiosensitive G2/M
cell cycle phase in D384 (18–27%) and U251 (17–41%)
cells. 750 lM meloxicam resulted in radiosensitization of
D384 (DMF:2.19) and U87 (DMF:1.25) cells, but not U251
cells (DMF:1.08). The selective COX-2 inhibitor meloxi-
cam exerted COX-2 independent growth inhibition and
radiosensitization of human glioma cells.
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Introduction
Malignant gliomas account for approximately 30% of all
intracranial tumors, with glioblastoma multiforme to be the
most frequent and aggressive type. For many years, sur-
gical resection followed by radiation therapy has been the
standard treatment for gliomas, resulting in a median sur-
vival of less than 1 year after initial diagnosis [1–3]. Since
the study of Stupp et al. [4], showing a significant pro-
longation of survival by additional administration of tem-
ozolomide, the new standard of care for glioblastoma
multiforme now consists of surgery, radiotherapy and
temozolomide [4]. However, regardless of treatment, al-
most all of these patients ultimately succumb to their dis-
ease. Further optimization of therapy is required.
The cyclooxygenase (COX) enzyme exists in two main
isoforms, COX-1 and COX-2. COX-1 is constitutively
expressed in most tissue types and plays a role in house-
keeping functions. COX-2 expression is low in most nor-
mal tissues and can be upregulated under various
pathological conditions and also by irradiation. Overex-
pression of COX-2 has been found to be important in the
development of several human tumor types (e.g. colon,
gastric, pancreatic) [5], including gliomas [6] and has been
associated with high tumor aggressiveness and poor pa-
tients’ prognosis [7, 8]. The COX-2 protein is overex-
pressed in the majority of gliomas, therefore it is
considered to be an attractive therapeutic target [6, 8, 9].
In recent years, drugs with high affinity to COX-2 and low
affinity to COX-1, the so-called selective COX-2 inhibitors,
have become available. An advantage of this selective
affinity is that COX-1 mediated processes are not affected.
Therewith, these compounds show a low probability of the
occurrence of side effects like gastroulceritis, dyspepsia, or
even acute renal failure. Selective inhibitors of COX-2 are
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prescribed for various inflammatory diseases (e.g. arthritis).
The anti-tumor effect of selective COX-2 inhibitors, re-
ported both in vitro and in vivo experimental studies [10–12],
supported the introduction of these compounds in the clinic.
However, the mechanism of action of these inhibitors is not
well understood. Angiogenesis regulation, inhibition of cell
proliferation as well as apoptosis induction have been re-
ported to be involved in their anti-tumor effect [5, 13, 14].
Interestingly, selective COX-2 inhibitors also demonstrated
to act as a radiosensitizer [5, 15–21]. The selective COX-2
inhibitor meloxicam has been shown to inhibit cell prolif-
eration of different cancer cell lines and animal tumors [10,
12, 22–25]. However, no data are available yet on glioma
cells. Differences in the profiles between meloxicam and
other selective COX-2 inhibitors are explained by its dif-
ferent chemical structure and its unique pharmacological
action on COX-2. The underlying molecular mechanism of
the anti-inflammatory action of many COX-2 inhibitors is
quite well understood, but it is not clear how meloxicam
exerts its anticancer effect. Since gliomas represent a group
of heterogeneous tumors, and often overexpress COX-2 [6,
9], a better understanding of the basic biology of gliomas and
on the response to COX-2 inhibition might contribute to the
improvement of glioma therapy.
The objective of the present study was to determine the
effectiveness of the COX-2 inhibitor meloxicam alone and
in combination with irradiation on cell proliferation, cell
survival and radiosensitization on human glioma cell lines,
with different COX-2 protein expression levels.
Materials and methods
Cell culture
The established human glioma cell line U87 was obtained
from the American Type Culture Collection. U251 cells were
isolated from a glioblastoma multiforme specimen [26] and
D384 cells were cloned from a cell line derived from an
astrocytoma [27]. Both U251 and D384 are established cell
lines and were kindly provided by Dr. C. H. Langeveld
(Dept. Pharmacology, Vrije Universiteit, Amsterdam, The
Netherlands) [27]. All cell lines were confirmed to be
mycoplasma free and cultured in DMEM supplemented with
10% fetal calf serum, 2% glutamine, 100 IU/ml penicillin,
and 100 IU/ml streptomycin. Cells were grown as mono-
layers in 25 cm2 culture flasks and were maintained in a
humidified 7% CO2 atmosphere at 37C.
Growth assay
1.105 (D384 and U251) or 1.106 (U87) cells/flask were
plated, a density that enables linear growth. Cells were
given 24 h to attach to the bottom of the culture flask, after
which cells were exposed to 250, 500 and 750 lM of
meloxicam (Boehringer Ingelheim, Germany) or vehicle
(0.38% DMSO). Duplicate culture flasks of each day were
trypsinized and counted each day for a maximum of 3 days
using coulter counter (Coulter ZTM series).
Clonogenic assay
Subconfluently growing D384, U251 and U87 cells were
exposed to 750 lM meloxicam or vehicle (0.38% DMSO)
for 24 h and irradiated with single doses of c-radiation (0–
6 Gy) using a 60Co source (Gammacell 200, Atomic En-
ergy of Canada Ltd). 150–5000 cells/flask were plated
immediately after irradiation for colony-forming ability in
medium without meloxicam. After 10 days, colonies were
fixed with 100% ethanol and stained with 10 % Giemsa
solution. Colonies containing more than 50 cells were
counted. Cell survival curves were estimated after nor-
malization for cytotoxicity induced by meloxicam alone.
Data from three independent experiments were combined
and the average survival levels were fitted by least squares
regression using the linear quadratic model. The Dose
Modifying Factor (DMF) (the ratio of the radiation dose
plus vehicle and the radiation dose plus meloxicam) was
estimated at a surviving fraction (SF) of 0.5. Survival
curves were analysed using Statistical Package for Social
Sciences (SPSS; Chicago, IL, USA) statistical software as
previously described by van Bree et al. [28].
Fluorescence-activated cell sorter (FACS) analysis
of cell cycle distribution
After treatment of 5.105 cells/flask with vehicle or 250, 500
and 750 lM meloxicam, cells were trypsinized and resus-
pended in fresh medium. Cells were washed twice in PBS,
centrifuged for 4 min at 1000 rpm, and fixed with 70%
ethanol. Subsequently, cells were incubated with RNAseA
(0.25 mg/ml) for 20 min at room temperature and stained
with propidium iodide (0.1 mg/ml) for 30 min in dark on
ice. DNA content of the cells was analyzed by FACS
(Becton Dickinson) with an acquisition of 50,000 events.
Western blotting
After 24 h treatment with vehicle or 750 lM meloxicam,
cells were scraped in ice-cold PBS and collected for
treatment with 25 ll lysis buffer (50 mM Tris/HCL, 1%
NP40, 0.5% Na-deoxycholate, 150 mM NaCl, 0.05% SDS,
and 1:1000 pefablock) to obtain whole cell lysates. Cell
lysates were kept on ice for 1 h and centrifuged at 14,000g
at 4C for 10 min. The protein concentration of the
supernatant was measured using the Bio-Rad Assay
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(BioRad Laboratories, Germany) according to the manu-
facturer’s instructions. A total of 100 lg protein was sub-
jected to 7.5% SDS-polyacrylamide gel electrophoresis and
transferred to a PVDF membrane (Immobilon-P, Milli-
pore). Membrane was blocked in 5% non-fat milk in TBST
(Tris buffered saline, 0.1% Tween 20) for 1 h at room
temperature. Subsequently, the membrane was incubated
with the primary antibody (1:1000 mouse-a-COX-2
monoclonal antibody, Cayman Chemical, USA) in TBST
(with 0.5 % non-fat milk) overnight at 4C. The blot was
washed 3 times in TBST (with 0.5% non-fat milk) and
incubated with the secondary antibody (1:1000 goat-a-
mouse-HRP, DAKO Cytomation, Denmark) in TBST (with
0.5% non-fat milk) for 1 h at room temperature. After
incubation, the membrane was washed in TBST (with 0.5%
non-fat milk) and developed using an ECL system
(Amersham Pharmacia, England) on a hyperfilm (Amer-
sham Bioscience, England).
Results
Effect of meloxicam on cell growth and cell survival
Meloxicam exposure to D384, U87 and U251 cells resulted
in a time and dose-dependent growth inhibitory response
(Fig. 1). An almost complete growth arrest was induced
after exposure to 750 lM meloxicam, which remained
arrested for up to 3 days. After 24 h of treatment of D384,
U87 and U251 cells with 750 lM meloxicam the surviving
fraction was 0.57, 0.81 and 0.74, respectively.
Combination of meloxicam with irradiation
To determine the radiosensitizing potential of meloxicam,
cells were incubated for 24 h with 750 lM meloxicam and
then irradiated. Cell survival curves (Fig. 2) show that
meloxicam treatment enhanced the radiation response of
D384 cells (DMF of 2.19, P < 0.01) and of U87 cells
(DMF of 1.25, P < 0.01), but not that of U251 cells (DMF
of 1.08, n.s.).
COX-2-protein expression
COX-2 protein expression levels were assessed to deter-
mine whether or not the growth inhibition and radioen-
hancement after meloxicam treatment were related to
COX-2. Subconfluently growing D384 and U251 cells did
not show COX-2 expression. U87 cells expressed COX-2
constitutively at a level exceeding the 10 ng reference
standard (Fig. 3).
Cell cycle distribution
The effect of meloxicam on cell cycle distribution was
analyzed by flow cytometry. As illustrated in the DNA
histograms in Fig. 4, both D384 and U251 cells accumu-
lated in the G2/M phase after 24 h of treatment with
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Fig. 1 Dose-dependent growth
inhibition after meloxicam
exposure. Subconfluently
growing D384, U87 and U251
cells were exposed to vehicle
(0.38% DMSO) (n), or to
250 lM (m), 500 lM (.), and
750 lM (r) meloxicam for
depicted exposure times. Error
bars represent SD of three
independent experiments and
are indicated for each data point
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750 lM meloxicam. Following exposure to meloxicam, the
fraction of U87 cells in the G0/G1 phase increased from 53
to 75% (Fig. 4).
Discussion
Previous studies have demonstrated tumor growth inhibi-
tion and radioenhancement by selective inhibition of the
COX-2 protein [11, 16–19, 15]. The COX-2 inhibitor
meloxicam was reported to inhibit growth of various tumor
cell types both in vitro and in vivo [10, 12, 22, 23, 29, 30].
Until now, neither the growth inhibitory capacity nor the
radiosensitizing potential of meloxicam was tested on hu-
man glioma cells.
The present study shows that meloxicam inhibits cell
growth of three glioma cell lines and significantly radio-
sensitizes two of them. Exposure to 750 lM meloxicam
almost completely suppressed cell growth, but only slightly
reduced cell survival. Our observations agree with other
reports, showing inhibition of cell proliferation at compa-
rable doses of meloxicam [24, 25, 31]. Since the glioma
cells we tested had different levels of constitutive COX-2
protein expression, the growth inhibitory response was
probably not related to the COX-2 protein level. COX-2
independent growth inhibition has also been reported by
Patel et al. [32] after treatment of human prostate cancer
cells with celecoxib or rofecoxib both in vitro and in vivo.
Furthermore, celecoxib was reported to inhibit growth of
9L rat gliosarcoma cells that were orthotopically trans-
planted in rat brains, leading to a decreased expression of
Bcl-2, Bcl-XL, phosphorlyated Akt and EGFR [11].
However Hsu et al. [33] reported celecoxib to induce
apoptosis by blocking the activation of anti-apoptotic Akt
in prostate cancer cells via an action that was independent
of Bcl-2.
Little information is available about the molecular
mechanisms involved in COX-2 mediated growth inhibi-
tion. Both cell cycle blockade and induction of apoptosis
are reported after in vitro exposure of cells to the inhibitors
meloxicam, celecoxib and rofecoxib. The meloxicam
concentration and exposure time we used in our experi-
ments did not result in the induction of apoptosis, but
caused a cell cycle arrest. Because cell cycle arrest was
induced at a concentration of meloxicam higher than nee-
ded for inhibition of COX-2 function, this effect was
probably independent of the COX-2 protein. COX-2
independent anti-tumor effects of selective COX-2 inhibi-
tors have recently been discussed in detail by Grosch et al.
[34].
Petersen et al [17], using the COX-2 inhibitor SC-236,
reported radioenhancement after treatment of U251 cells
(DMF of 1.4 at SF 0.1). The absence of a radioenhance-
ment on U251 cells in the present data (Fig. 2), might be
ascribed to a different mechanism of action of the inhibitor
meloxicam. Meloxicam enhanced the radiation response of
D384 and U87 (Fig. 2). Because only U87 cells constitu-
tively expressed the COX-2 protein, this observation sug-
gests that the radiosensitizing effect was not related to the
COX-2 protein level at the time of irradiation. However,
using the selective COX-2 inhibitor NS-398, Pyo et al. [18]
found a preference for radiosensitization of cells that ex-
press COX-2.
Cells in the G2/M phase of cell cycle are known to be
sensitive to radiation [35]. Previous studies reported
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Fig. 2 Radiation cell survival
curves for D384 cells, U87 cells
and U251 cells. Cells were pre-
treated for 24 h either with
vehicle (0.38% DMSO) (n) or
750 lM meloxicam (m). Error
bars represent SD of three
independent experiments. (n.s.
is not significant)
C
XO
2
- 83D
4 78U
52U
1
Fig. 3 Representative western blot showing COX-2 expression in
D384, U87 and U251 cells relative to the reference standard
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accumulation of cells into the G2/M phase by inhibitors of
the COX-2 protein [19, 36]. The radiosensitizing effect of
meloxicam we observed in our experiments was probably
not caused by cell cycle redistribution (cf. Figs. 2 and 4).
Growth inhibition and radiosensitization can be medi-
ated by the prostaglandins. The COX-enzymes are the rate-
limiting enzymes in the prostaglandin pathway, i.e. the
conversion of arachidonic acid to prostaglandins. The
Fig. 4 FACS analysis (n=2) of
D384, U87 and U251 cell cycle
distribution 24 h following
exposure to 750 lM meloxicam
or vehicle (0.38% DMSO).
Proportions of G1, S- and G2/M
phase are given in percent
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COX-2 enzyme is responsible for the synthesis of prosta-
glandin subtypes involved in pathological conditions. The
major metabolite of COX-2 is PGE2, which is reported to
inhibit apoptosis [37] and to act as radioprotector [38, 39].
Hence, the radiosensitizing action of meloxicam might be
ascribed to inhibition of the PGE2 production, as previ-
ously reported [23]. Kang et al [40] reported radiosensiti-
zation of U87 cells by celecoxib after high dose irradiation
in vitro by PGE2 inhibition. This phenomenon might also
explain our data, although the meloxicam concentration in
our experiments was higher than reported to be required for
inhibition of PGE2 production [19, 41]. Experimental
studies on the growth inhibitory and radiosensitizing ef-
fects of meloxicam should focus on PGE2 synthesis and on
apoptosis induction.
A recent report showed that meloxicam may exert its
anticancer effect by binding of Cu(II)-complexes of me-
loxicam with the DNA backbone, resulting in DNA dis-
tortion [42]. Further studies should attempt to determine a
possible interaction of DNA-intercalated Cu(II)-meloxicam
complexes with irradiation and the effect on the induction
and repair of DNA damage.
The present findings on three human glioma cell lines
demonstrate that the COX-2 inhibitor meloxicam inhibits
cell proliferation and may enhance the radiation response,
independent of COX-2 protein expression. Because of the
radiosensitizing potential of meloxicam and in view of the
recently reported interaction between irradiation and cel-
ecoxib [40] as well as between temozolomide and celec-
oxib [43] in experimental gliomas, selective COX-2
inhibitors yield promising perspective to further improve
the therapy of glioma patients.
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